This report identifies the genital herpes treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to genital herpes treatment market.
Globally North America dominated the market for genital herpes treatment in 2015 with highest market share due to strong network of healthcare setup and people having good awareness about sexually transmitted diseases/infections. North America was followed by Europe as the second largest regional market for genital herpes treatment. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to increasing awareness about genital herpes treatment and rapidly developing hospital network in the region.
This report on global genital herpes treatment covers different type of genital herpes treatment product types, distribution channels and market size in various geographical regions.
On the basis of product classes of genital herpes treatment, this report is segmented into three major classes covering all major product types for the genital herpes treatment as follows: Acyclovir, Famciclovir, and Valacyclovir
On the basis of distribution channels for proving medications of genital herpes treatment, this report is segmented into three major distribution channels covering all major available distribution channels for the genital herpes treatment as follows: Hospital Pharmacies, General Pharmacies and Drug stores
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for genital herpes treatment in each of the region.
This report identifies all the major companies operating in the global Genital Herpes Treatment market. Some of the major companies’ profiles in detail are as follows:
Teva Pharmaceuticals Inc.
Ranbaxy Laboratories Ltd.
Mylan Pharmaceuticals Inc.
Dr. Reddy’s laboratories, ltd.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Genital Herpes Treatment – Market Forces
4.1.1. Increasing cases of sexually transmitted diseases & increasing awareness about STD’s
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Genital Herpes Treatment – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Genital Herpes Treatment Market, By Product Type
7. Genital Herpes Treatment Market, By Treatment Distribution Channel
7.1. Hospital Pharmacies
7.2. General Pharmacies
7.3. Drug stores
8. Genital Herpes Treatment Market, By Geography
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Genital Herpes Treatment – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
10.1. Teva Pharmaceuticals Inc.
10.3. Ranbaxy Laboratories Ltd.
10.4. Mylan Pharmaceuticals Inc.
10.5. Hospira Inc.
10.6. Apotheca Inc.
10.7. Novartis AG
10.8. Dr. Reddy’s laboratories, ltd.
10.9. Novopharm Ltd.
10.10. Sandoz Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.4. Expert Insights